Recent studies showed that 50%-55.6% of ALK-positive NSCLC patients were PD-L1-positive (TPS ≥ 1%) and 16-30.6% had high expression (TPS ≥ 50%) 39, 42. This evidence concerns the gene CD274 and non-small cell lung carcinoma.